Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A1chieve study.

Background: The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.

Materials And Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from East India.

Resistant prolactinoma: Is it monoclonal or polyclonal?

Prolactinomas are solitary benign neoplasms and resistance to dopamine agonists occur in a small percentage of prolactinomas. Multiple pituitary adenomas are reported in less than 1% of pituitary adenomas and rarely result in resistant prolactinoma. We recently encountered an interesting patient of hyperprolactinemia with multiple pituitary microadenomas.

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.

Diabetes in young--unusual case presentation.

Diabetes in young is increasing in prevalence with each decade. Phenotypic features like obesity and acanthosis nigricans characterize type 2 diabetes, whereas autoimmune diseases like vitiligo and hypothyroidism suggest type 1 diabetes. We recently encountered a young boy with vitiligo who presented with hyperglycemia, but not associated with ketonuria and has underlying chronic pancreatitis with secondary diabetes.